|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.268 SEK | +2.42% |
|
+0.32% | -35.63% |
| 06-08 | Irlab shares trade ex-rights on Nasdaq Stockholm following rights issue | FW |
| 06-05 | IRLAB Therapeutics AB Announces Board Elections, Effective June 5, 2026 | CI |
Company Valuation: IRLAB Therapeutics AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,173 | 2,277 | 1,987 | 389 | 557.6 | 105.2 | 105.2 | - |
| Change | - | 4.76% | -12.75% | -80.42% | 43.33% | -81.14% | 0% | - |
| Enterprise Value (EV) | 2,173 | 1,875 | 1,734 | 277.7 | 494.2 | 105.2 | 105.2 | 105.2 |
| Change | - | -13.73% | -7.53% | -83.98% | 77.96% | -78.72% | 0% | 0% |
| P/E Ratio | -21.9x | 44x | -17.5x | -2.19x | -6.72x | - | - | - |
| PBR | - | - | 6.83x | - | 17.1x | - | - | - |
| PEG | - | -0x | 0x | -0x | 0.1x | - | - | - |
| Capitalization / Revenue | - | 11x | 32.5x | 68.5x | 5.89x | 2.91x | 1.03x | 0.74x |
| EV / Revenue | - | 0x | 0x | 0x | 0x | 1.87x | 1.03x | 0.74x |
| EV / EBITDA | - | 0x | -0x | -0x | -0x | -1.18x | -3.81x | 2.82x |
| EV / EBIT | - | 0x | -0x | -0x | -0x | -1.13x | -3.33x | 3.16x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.92 | 1 | -2.19 | -3.43 | -1.6 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 207.8 | 61.14 | 5.678 | 94.63 | 57.46 | 102 | 141.8 |
| EBITDA 1 | - | 56.05 | -108.3 | -176.4 | -70.53 | -89.08 | -27.6 | 37.3 |
| EBIT 1 | - | 52.58 | -113.1 | -180.8 | -75.11 | -93.4 | -31.6 | 33.3 |
| Net income 1 | -91.65 | 51.78 | -113.4 | -177.8 | -83.13 | -110 | -32.6 | 33.3 |
| Net Debt | - | -401.9 | -252.8 | -111.3 | -63.38 | - | - | - |
| Reference price 2 | 42.000 | 44.000 | 38.300 | 7.500 | 10.750 | 1.238 | 1.238 | 1.238 |
| Nbr of stocks (in thousands) | 51,748 | 51,748 | 51,868 | 51,868 | 51,868 | 84,938 | 84,938 | - |
| Announcement Date | 15/04/21 | 23/02/22 | 23/02/23 | 07/02/24 | 12/02/25 | 25/02/26 | - | - |
1SEK in Million2SEK
Estimates
P/E Ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 11.09M | |
| 33.25x | 12.09x | 24.89x | 0.6% | 1,013B | |
| 25.49x | 5.87x | 15.97x | 2.24% | 574B | |
| 27.54x | 6.71x | 13.71x | 3.05% | 397B | |
| 17.38x | 4.29x | 10.55x | 3.1% | 324B | |
| 22.74x | 4.73x | 13.45x | 1.85% | 280B | |
| 20.72x | 5.35x | 13x | 3.04% | 273B | |
| 21.96x | 5.91x | 10.33x | 2.99% | 182B | |
| 12.52x | 4.69x | 9.6x | 4.01% | 194B | |
| -43.47x | 5.27x | 29.72x | 2.67% | 151B | |
| Average | 15.35x | 6.10x | 15.69x | 2.62% | 338.87B | |
| Weighted average by Cap. | 22.66x | 7.45x | 17.35x | 2.12% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IRLAB A Stock
- Valuation IRLAB Therapeutics AB
Select your edition
All financial news and data tailored to specific country editions
